Cadrenal Therapeutics Inc. announced the resignation of Robert Lisicki, a Class II Director on the company's board, effective immediately as of July 15, 2025. The company clarified that his departure was not due to any disagreements regarding its operations, policies, or practices. The board will proceed with addressing this change in their upcoming meetings.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-065710), on July 18, 2025, and is solely responsible for the information contained therein.